Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 15/20 | 0.76 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.52 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17054237 | 1.00 | KCNK3 (0.76) | KCNK3CSNK1DCSNK1E | |
| SCHEMBL14791443 | 0.86 | KCNK3 (1.00) | KCNK3 | |
| SCHEMBL14783905 | 0.86 | KCNK3 (1.00) | KCNK3 | |
| SCHEMBL16211155 | 0.86 | KCNK3 (1.00) | KCNK3 | |
| SCHEMBL14784424 | 0.86 | KCNK3 (1.00) | KCNK3 | |
| SCHEMBL17220350 | 0.85 | KCNK3 (0.64) | KCNK3CSNK1DCSNK1E | |
| SCHEMBL16216972 | 0.82 | KCNK3 (0.90) | KCNK3 | |
| SCHEMBL16211021 | 0.81 | KCNK3 (1.00) | KCNK3 | |
| SCHEMBL14791489 | 0.81 | KCNK3 (1.00) | KCNK3 | |
| SCHEMBL16210965 | 0.79 | KCNK3 (1.00) | KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598410-B2 | Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-C]pyridines, their use as medicament, and pharmaceutical preparations comprising them | SANOFI (FR) | 2017-03-21 | — | — | US | disclosed |
| US-9598410-B2 | Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-C]pyridines, their use as medicament, and pharmaceutical preparations comprising them | SANOFI (FR) | 2017-03-21 | — | — | US | disclosed |
| US-20160060259-A1 | Substituted 4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-C]Pyridines, Their Use as Medicament, and Pharmaceutical Preparations Comprising Them | SANOFI (FR) | 2016-03-03 | — | — | US | disclosed |
| US-20160060259-A1 | Substituted 4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-C]Pyridines, Their Use as Medicament, and Pharmaceutical Preparations Comprising Them | SANOFI (FR) | 2016-03-03 | — | — | US | disclosed |
| EP-2755973-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINES, THEIR USE AS MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI SA (FR) | 2015-11-04 | — | — | EP | disclosed |
| EP-2755973-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINES, THEIR USE AS MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI SA (FR) | 2015-11-04 | — | — | EP | disclosed |
| US-9127001-B2 | Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them | SANOFI (FR) | 2015-09-08 | — | — | US | disclosed |
| US-9127001-B2 | Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them | SANOFI (FR) | 2015-09-08 | — | — | US | disclosed |
| US-20140330009-A1 | Substituted 4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-C]Pyridines, Their Use as Medicament, and Pharmaceutical Preparations Comprising Them | SANOFI (FR) | 2014-11-06 | — | — | US | disclosed |
| US-20140330009-A1 | Substituted 4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-C]Pyridines, Their Use as Medicament, and Pharmaceutical Preparations Comprising Them | SANOFI (FR) | 2014-11-06 | — | — | US | disclosed |
| WO-2013037415-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINES, THEIR USE AS MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI (FR) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013037914-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINES, THEIR USE AS MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI (FR) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060259-A1 | Substituted 4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-C]Pyridines, Their Use as Medicament, and Pharmaceutical Preparations Comprising Them | KCNA1, KCNT1, CACNA1I | KCNK3 30/4885CSNK1D 876/4885CSNK1E 1299/4885 |
| US-20140330009-A1 | Substituted 4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-C]Pyridines, Their Use as Medicament, and Pharmaceutical Preparations Comprising Them | KCNA1, KCNT1, KCNJ11 | KCNK3 29/4885CSNK1D 920/4885CSNK1E 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.